ArticleMedical oncology (Northwood, London, England)2001
Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma.
Article in Medical oncology (Northwood, London, England), 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.International journal of molecular sciences · 2024Pooled it
- Digital and Manual Assessment of Intrafollicular Ki-67,Diagnostics (Basel, Switzerland) · 2026Article
- Comparison of Ki67 Proliferation Index in Gastrointestinal Non-Hodgkin Large B-Cell Lymphomas: The Conventional Method of Evaluation or AI Evaluation?Diagnostics (Basel, Switzerland) · 2023Article
- Comparison of Ki-67 Labeling Index Patterns of Diffuse Large B-Cell Lymphomas and Burkitt Lymphomas Using Image Analysis: A Multicenter Study.Diagnostics (Basel, Switzerland) · 2021Article
- A Multicenter Retrospective Study of 58 Patients With Primary Thyroid Diffuse Large B Cell Lymphoma.Frontiers in endocrinology · 2020Article
- Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.The oncologist · 2018Article
- miR-31 and miR-17-5p levels change during transformation of follicular lymphoma.Human pathology · 2016Article
- High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy.International journal of hematology · 2015Article
- Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type.Medical oncology (Northwood, London, England) · 2014Article
- Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy.The Journal of experimental medicine · 2014Article
- MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy.Cancer science · 2013Article
- Software-automated counting of Ki-67 proliferation index correlates with pathologic grade and disease progression of follicular lymphomas.American journal of clinical pathology · 2013Article
- Immunophenotyping of chronic B-cell neoplasms: flow cytometry versus immunohistochemistry.Hematology reports · 2012Article
- Significance of Bcl-2 and Bcl-6 immunostaining in B-Non Hodgkin's lymphoma.Hematology reports · 2011Article
- No Prognostic Impact of p53 and P-Glycoprotein Expression in Patients with Diffuse Large B-Cell Lymphoma.ISRN oncology · 2011Article
- Malignant lymphomas (ML) and HIV infection in Tanzania.Journal of experimental & clinical cancer research : CR · 2008Article
- Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas.Biomarker insights · 2007Article
- Ki-67 proliferative marker in lymph node aspirates of patients with non-Hodgkin's lymphoma.Medical oncology (Northwood, London, England) · 2006Article
- Article
- Follicular lymphoma in Osaka, Japan: histological features and chronological change.International journal of hematology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed 104 patients with non-Hodgkin's lymphoma, follicular or diffuse large-B-cell-type lymphoma, in order to evaluate the correlation between clinical characteristics and immunohistochemical parameters. Immunostaining was performed by means of monoclonal antibodies against Ki-67, bcl-2, and p53 expression. Forty-nine of the patients showed follicular lymphoma. A high expression of bcl-2 was found in 93%, high expression of p53 in 57%, and low expression of Ki-67 in 96%. Follicular lymphoma grade III showed a p53 expression (p = 0.07) slightly higher than follicular lymphoma grades I and II, not reaching statistical significance. Follicular lymphoma grades I and II tended to express lower Ki-67 and higher levels of bcl-2 expression than grade III (p = 0.06). Fifty-five cases showed diffuse large-B-cell lymphoma. Among them, bcl-2 was absent in 39%, whereas p53 and Ki-67 expression were high in 38%. In the diffuse large-B-cell lymphomas, a high bcl-2 expression correlated with stages III and IV (p = 0.03) and involvement of more than one extranodal area (p = 0.03). High Ki-67 expression was also associated to extranodal involvement of more than one area (p = 0.03). Overall survival of patients did not show statistically significant differences regarding Ki-67, bcl-2, and p53 tumoral expression. Prognostic factors for overall survival in the multivariate analysis were age (p = 0.02) and LDH (p = 0.003). Time to progression was worse among follicular lymphoma with high p53 expression than with mild/moderate p53 expression (p = 0.009).
Indexed as
Identifiers
11778965What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.